Clean Science & Technology Ltd. · NSE:CLEAN

Clean Science & Technology — Q2 FY2026 Earnings Presentation

23 slides from Clean Science & Technology's earnings presentation, Nov 6, 2025

  1. Slide 1: Exchange filing cover letter for investor presentation

    06.11.2025 To, BSE Limited National Stock Exchange of India Limited Phiroze JeeJeebhoy Towers, Exchange Plaza, Plot no. C/1, Dalal Street, G Block, Bandra-Kurla Complex Fort, Mumbai – 400 001 Bandra (E), Mumbai - 400 051 Scrip Code: 543318 Trading Symbol: CLEAN Subject: Investor Presentation. Dear S

  2. Slide 2: Clean Science and Technology Ltd. Investor Presentation Q2 FY2026

    Clean Science and Technology Ltd. Investor Presentation Q2 FY 2026 I NOVEMBER 2025

  3. Slide 3: Safe Harbour

    SAFE HARBOUR This investor presentation has been prepared by Clean Science and Technology Limited (“CSTL”) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered o

  4. Slide 4: Q2 FY2026 Business Update

    Q2 FY 2026 Business Update

  5. Slide 5: Q2 FY2026 Update

    Q2 FY2026 UPDATE Favourable product mix led to resilient EBITDA margins Revenue in INR Crore 195 225 217 228 232 245 220 211 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 44.9% 44.4% 45.5% 42.1% 44.8% 43.8% 46.4% 43.7% 34.7% 36.6% 37.3% 34.4% 34.1% 35.7% 33.6% 32.5% 9.0% 8.7% 9.6%

  6. Slide 6: Q2 FY2026 P&L Overview

    Q2 FY2026 P&L OVERVIEW Benefits of operating leverage to kick-in as newly launched products scale in revenue P&L (INR Crore) STANDALONE CONSOLIDATED Particular Q2 FY2026 Q1 FY2026 Q-o-Q (%) Q2 FY2025 Y-o-Y (%) Q2 FY2026 Q1 FY2026 Q-o-Q (%) Q2 FY2025 Y-o-Y (%) Sale of products 206 217 (5)% 225 (8)% 2

  7. Slide 7: H1 FY2026 P&L Overview

    H1 FY2026 P&L OVERVIEW Steady profitability with enhanced contribution from new product launches P&L (INR Crore) STANDALONE CONSOLIDATED Particular H1FY2026 H1FY2025 Y-o-Y (%) H1 FY2026 H1 FY2025 Y-o-Y (%) Sale of products 423 439 (4)% 480 456 5% Other operating income 8 6 8 6 Total Revenue 431 445

  8. Slide 8: H1 FY2026 Balance Sheet Overview

    H1 FY2026 BALANCE SHEET OVERVIEW Healthy cash balance to fund ongoing capex Standalone Balance Sheet As at As at Consolidated Balance Sheet As at As at (INR Crore) 30-Sept.-2025 31-March-2025 (INR Crore) 30-Sept.-2025 31-March-2025 Assets Assets Non-current assets Non-current assets Fixed Assets 347

  9. Slide 9: Revenue Profile – H1 FY2026

    REVENUE PROFILE – H1 FY 2026 Performance segment share increased led by higher sales of HALS series REVENUE MIX BY SEGMENT REVENUE MIX BY GEOGRAPHY 9% 13% 9% 10% 16% 36% 20% 38% 17% 21% H1 FY’26 H1 FY’25 H1 FY’25 H1 FY’26 75% 70% 14% 16% 17% 19% Performance Pharma & Agro FMCG China India Europe Amer

  10. Slide 10: Corporate presentation

    Corporate presentation

  11. Slide 11: Clean Science and Technology at a Glance

    CLEAN SCIENCE AND TECHNOLOGY AT A GLANCE A brief Introduction about the Company ➢ One of the fastest growing and among the most profitable fine and specialty chemical companies globally. Among the largest manufacturers of certain specialty chemicals developed in-house. ➢ Among the few global organiz

  12. Slide 12: Company Evolution

    COMPANY EVOLUTION Continuous R&D and Innovation has led to new product launches on a consistent basis YEAR 2009 2011 2014 2018 2020 2021 2022 2023 2024 2025 REVENUES (INR Crore) 1 19 120 241 419 512 685 936 789 967 ➢ Commercialized largest plant for Genesis: HALS from India 2025 ➢ Technocrat Promote

  13. Slide 13: Diversified Product Profile Serving Critical End-User Industries

    DIVERSIFIED PRODUCT PROFILE SERVING CRITICAL END-USER INDUSTRIES Largest capacity in the world for our flagship products PERFORMANCE PHARMA AND AGRO FMCG CHEMICALS INTERMEDIATES CHEMICALS MEHQ (Monomethyl Ether of Hydroquinone) Guaiacol 4-MAP (4-Methoxy Acetophenone) ➢ Used as polymerization inhibit

  14. Slide 14: Key Differentiators That Add Value

    KEY DIFFERENTIATORS THAT ADD VALUE Unique benefits that set our business apart from competition INNOVATION GLOBAL LEADERS PREFERRED PARTNER STATE-OF-THE-ART Strategic process innovation Among the largest OF CHOICE Multiple, automated and new product producers globally of Strong and long term manufac

  15. Slide 15: Steadfast Focus on Research & Development

    STEADFAST FOCUS ON RESEARCH & DEVELOPMENT Pioneered commercialization of catalytic reactions Research and Development team’s focus areas Enhance our existing catalyst Develop products with high demand Expand product portfolio in the 1 systems to further optimize yield 2 performance chemical segment

  16. Slide 16: Cohesive and Technocrat Promoters

    COHESIVE AND TECHNOCRAT PROMOTERS Strong visibility on longevity of Promoters’ engagement in the business Over 3 decades of work experience in Over 19 years of experience in the the chemical industry. chemical industry. Industry experience of over 5 decades Bachelor of Chemical Technology – Institut

  17. Slide 17: Robust Corporate Governance

    ROBUST CORPORATE GOVERNANCE Distinguished Board of Directors and reputed financial market participants underscore sound governance PROFILE OF NON-EXECUTIVE, INDEPENDENT DIRECTORS ON THE BOARD PRADEEP RATHI PROF. G. D. YADAV Sanjay Kothari Chairman and Non-Executive Director Non-Executive, Independen

  18. Slide 18: Continued Commitment Towards Sustainability and ESG

    CONTINUED COMMITMENT TOWARDS SUSTAINABILITY AND ESG Sustainability and ESG initiatives are embedded in our long term growth strategy ENVIRONMENT EMPATHY (E) SOCIAL RESPONSIBILITY (S) CORPORATE GOVERNANCE (G) ➢ Utilize resources efficiently, reduce waste and minimize emissions as part of our ➢ Total

  19. Slide 19: Advanced Manufacturing Facilities Designed by In-House Engineering Team

    ADVANCED MANUFACTURING FACILITIES DESIGNED BY IN-HOUSE ENGINEERING TEAM 3 independent functional units under CSTL at Kurkumbh Industrial Area, Maharashtra with dedicated lines for each product UNIT 1 NO plant closure notice received from pollution 7 plants control board Total area – 30,000 sq.m All

  20. Slide 20: Commercialized Largest Facility for HALS from India

    COMMERCIALIZED LARGEST FACILITY FOR HALS FROM INDIA Largest facility of Clean Science Group housed in its wholly owned subsidiary, Clean Fino Chem Ltd. at Kurkumbh Industrial Area, Maharashtra UNIT 4 Commercialized in March 2024 Total area – 1,32,700 sq.mtrs. (34 acres) Cost advantage - Tax incentiv

  21. Slide 21: Strong Financial Performance

    STRONG FINANCIAL PERFORMANCE Resilient performance demonstrated over business cycles maintaining a debt free balance sheet REVENUE EBITDA & EBITDA% PAT & PAT% CAGR of 16% CAGR of 11% CAGR of 10% 512 685 936 789 922 259 300 403 337 399 198 229 304 248 292 51% 39% 44% 34% 43% 43% 44% 33% 32% 32% FY 20

  22. Slide 22: Our Key Growth Drivers

    KEY GROWTH LEVERS Strategic initiatives and investments aimed at long term sustainable growth FOCUS ON ESG AND SIGNIFICANT SUSTAINABILITY GREENFIELD CAPEX Capitalise on our core philosophy Planned capex on track for of clean and green chemistry to commercialising new series of address opportunities

  23. Slide 23: Thank You

    THANK YOU For further information, please contact: PRATIK BORA Email: pratik@cleanscience.co.in Clean Science and Technology Limited Website: https://www.cleanscience.co.in/

Clean Science and Technology — Q2 FY2026 Earnings Presentation on 6ix